Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

Up 215% YTD, Should You Grab This Growth Stock Before It’s Too Late?

Celcuity (CELC), a clinical-stage biotechnology company, has quietly surged more than 215% year-to-date, turning heads on Wall Street. 

While larger names in oncology dominate headlines, this under-the-radar cancer drug developer is making a name for itself by advancing an innovative approach to treating hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer, one of the most common and deadly subtypes of breast cancer.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.